SCOTTSDALE, Ariz., July 22, 2025 /PRNewswire/ -- A LifeStance Health survey released today reveals "stressflation" is affecting most Americans, with 83% reporting financial stress driven by inflation, mass layoffs, the rising cost of living and recession fears. Millennials and Gen Z report the most significant mental health impacts.
The number of respondents who have been deterred from seeking mental health care due to financial constraints remains consistently high (60%), increasing two percentage points from 2024. Those experiencing high financial stress levels are more than twice as likely to forgo mental health treatment due to cost, highlighting a mental health gap where financial strain exacerbates mental health challenges while limiting access to care.
While an overwhelming majority of Americans believe mental health care is just as important as physical health care (93%), financial barriers are disrupting treatment, with nearly half (47%) of respondents reporting that they skipped a therapy session due to cost. However, many are returning to therapy sooner after a cost-related break compared to last year (33% resumed within a week, up from 8% in 2024).
"People are prioritizing their mental health like never before, but economic challenges — from increased grocery bills to housing costs — are making it harder for many to get the care they need," said Dr. Rachel Dalthorp, Executive Medical Director, LifeStance Health. "As demand for mental health care continues to grow, our health care system must rise to meet that need by improving access to high-quality, affordable mental health care."
Key findings include:
1. Most Americans are experiencing financial stress driven by factors like inflation, the rising cost of living and recession fears, pointing to a heightened need for mental health care.
2. Those experiencing high financial stress levels are more than twice as likely to forgo mental health treatment due to cost.
3. Mental health care is widely viewed as equally important – or even more important – than physical health care, especially among younger generations.
4. Overall, cost is deterring more people from starting therapy.
5. Financial barriers are disrupting consistent treatment, with increased grocery prices being a key deterrent in accessing care.
6. Respondents are returning to therapy more quickly in 2025 than last year despite cost, suggesting a growing prioritization of mental health.
Methodology
On behalf of LifeStance Health, Researchscape International conducted an online survey of 1,026 U.S. adults aged 18 and older. The survey was fielded from June 4 to June 5, 2025. The credibility interval is plus or minus four percentage points for questions answered by all respondents. The data was weighted to the U.S. population by nine demographic questions.
ABOUT LIFESTANCE HEALTH
Founded in 2017, LifeStance (NASDAQ: LFST) is reimagining mental health. We are one of the nation's largest providers of virtual and in-person outpatient mental healthcare for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental healthcare. LifeStance and its supported practices employ approximately 7,500 psychiatrists, advanced practice nurses, psychologists and therapists and operate across 33 states and more than 550 centers. To learn more, please visit www.LifeStance.com.
Last Trade: | US$5.51 |
Daily Change: | 0.16 2.99 |
Daily Volume: | 1,158,486 |
Market Cap: | US$2.140B |
August 26, 2025 August 07, 2025 May 07, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load